Chybami se člověk učí … dělat chyby jiné a jinak

prof. RNDr. Stanislav Komenda DrSc

Interní Med. 2006; 8(5)

Current opinion on patients with increased cardiovascular risk

prof. MUDr. Jiří Vítovec CSc, prof. MUDr. Jindřich Špinar CSc., FESC

Interní Med. 2006; 8(5): 214-218  

Authors present a review of algorhytms in primary prevention of high-risk patients and secondary prevention of cardiovascular diseases. Besides nonpharmacological methods the pharmacotherapy is emphasized: renin-angiotensin system inhibitors – ACE-inhibitors and sartans, beta-blockers, antiplatelet treatment, acetylosalicylic acid with clopidogrel and statins.

Diabetes mellitus and hypertension

MUDr. Erik Hollay, MUDr. Pavlína Piťhová, doc. MUDr. Milan Kvapil CSc

Interní Med. 2006; 8(5): 219-222  

Arterial hypertension is a disease with high prevalence in developed countries and continues to be a current problem. From the diabetelogy point of view it is considered to be one of the components of metabolic syndrome and belongs to the most important risk factors of cardiovascular mortality. Authors attempted to summarize the treatment modalities of arterial hypertension in diabetic patients in connection with results of clinical trials.

Lipid-lowering treatment and metabolic syndrome

MUDr. Tomáš Štulc

Interní Med. 2006; 8(5): 223-226  

During the last decades, metabolic syndrome has become an important healthcare problem worldwide. Main components of metabolic syndrome are insulin resistance (resulting often in impaired glucose tolerance and diabetes mellitus), dyslipidemia, hypertension and abdominal obesity. Incidence of metabolic syndrome is high and it substantially increases the risk of cardiovascular diseases. Dyslipidemia is a prominent factor contributing to the increased cardiovascular risk in metabolic syndrome, and lipid-lowering therapy plays an important role in treating patients with this disorder. Most patients with dyslipidemia are treated with statins and/or fibrates....

NEW DRUGS FOR TREATMENT OF CHRONIC VIRAL HEPATITIS

doc. MUDr. Petr Husa CSc

Interní Med. 2006; 8(5): 227-230  

Chronic viral hepatitis represents a serious health problem also in the beginning of the 21st century. Four drugs for chronic hepatitis B treatment have been approved in the Czech Republic – pegylated interferon alpha-2a, standard interferon alpha, lamivudine and adefovir dipivoxil. Entecavir, has been approved in United States since March, 2005. Treatment with pegylated interferon alpha and ribavirin has been the standard of chronic hepatitis C therapy for about 5 years. It is very probable that this situation will be without changes for some more years.

Peptic gastric and duodenal ulcer disease - current trends of treatment

prof. MUDr. Petr Dítě DrSc

Interní Med. 2006; 8(5): 231-234  

Current treatment of peptic ulcer disease is based on limitation of the effect of aggressive factors, in particular hydrochloride acid, presence of H. pylori bacteria on mucosa of stomach and drug related damage to gastric mucosa. The importance of diet is smaller than expected years ago, diet is individualized and contains exclusion of generally known irritating components of diet and smoking. Drugs are dominated by proton pump inhibitors. Medications are the first choice in therapy of uncomplicated ulcers and basic treatment in eradication of H. pylori. In prevention of damage of gastric mucosa, e.g. by medications (nonsteroidal anti-inflammatory...

The cystic fibrosis

MUDr. Petr Jakubec

Interní Med. 2006; 8(5): 235-239  

Cystic fibrosis is the most lethal autosomal recessive disease in Caucasians. The most serious pathological changes are situated in airways, lung and pancreas, but cystic fibrosis afflicts other parts of the digestive tract, genital system and skin. Heart is involved rarely too. The most common cause of death are the lung damage and cardiopulmonary failure. The length of life of CF patients was only a few of years in the past. The average survival is about 35 years owing to management advances today. The gene therapy is great hope to the future.

The antiphospholipid syndrome

MUDr. Alena Buliková, prof. MUDr. Miroslav Penka CSc

Interní Med. 2006; 8(5): 240-243  

The antiphospholipid syndrome is a clinicopathologic syndrome in which antiphospholipid antibodies (APA) are though to be involved in the development of thrombosis and/or pregnancy complications. The authors present a review of mechanisms by which these autoantibodies promote thrombosis, they introduce a new international consensus statement on an update of the classification criteria for antiphospholipid syndrome including wide spectrum of the clinical manifestations. They also list diagnostic and treatment possibilities.

Chronotherapy of the most common rheumatological diseases, especcialy rheumatoid arthritis and deforming osteoarthrosis

MUDr. Julius Vachtenheim CSc

Interní Med. 2006; 8(5): 244-246  

The aim of this short review is to summarize our experience with chronotherapy, especially with regard to chronobiology of the two most common rheumatological diseases diagnosed in clinical practice. These include rheumatoid arthritis as an inflammatory disease and deforming osteoarthrosis as a noninflammatory arthropathy. Special emphasis is given to systemic and local therapy of these diseases.

kongres Interní medicína pro praxi vzdělával za pomoci kazuistik

MUDr. Hana Šarapatková, Mgr. Iva Daňková

Interní Med. 2006; 8(5): 257  

Tyreotoxikóza a kost

MUDr. Yvona Hrčková, MUDr. Hana Šarapatková, Mgr. Jana Vrbková, MUDr. Jarmila Indráková

Interní Med. 2006; 8(5): 249-251  

ETHICAL ASPECTS OF MALE RITUAL CIRCUMCISION

MUDr. Miroslav Pešl, MUDr. Libor Zámečník, MUDr. Viktor Soukup, MUDr. Ivan Pavlík, prof. MUDr. Jan Dvořáček DrSc

Interní Med. 2006; 8(5): 247-248  

The article questions a fact, whether a doctor, performing ritual circumcision, does not get into the conflict with principles of medical ethics because of performing an operation due to religious and not medical reasons. Authors present arguments, why such a doctor practices ethically.

Management ošetřování dekubitů

Bc. Lenka Šeflová, Mgr. Irena Beránková

Interní Med. 2006; 8(5): 252-256